Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-H3


Brief Information

Name:CD276 antigen
Target Synonym:B7 homolog 3,PSEC0249,UNQ309/PRO352,B7-H3,CD276 antigen,B7H3,CD276,CD276 Molecule,Costimulatory Molecule,4Ig-B7-H3,B7RP-2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:14
Lastest Research Phase:NDA/BLA


Project item Indications Research phase Cooperation demands
BDA202203 B7H3+ and PD-L1+/low cancer CMC development License-out or co-development
BDA202206 Broad cancer PCC License-out or co-development the global right
BEX202203 Solid tumor IND License-out or co-development

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

B73-H52E2-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human B7-H3, His Tag (Cat. No. B73-H52E2) inhibits Anti-CD3-induced proliferation of PBMC. The EC50 for this effect is 2.24-3.36 μg/mL (Routinely tested).

Cynomolgus B7-H3, His TagCynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) ELISA bioactivity

Immobilized Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

Cynomolgus B7-H3, His Tag (Cat. No. ) MALS images

The purity of Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) is more than 90% and the molecular weight of this protein is around 53-75 kDa verified by SEC-MALS.

Cynomolgus B7-H3, His TagCynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) ELISA bioactivity

Immobilized Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

Synonym Name

B7-H3,CD276,B7 homolog 3


B7 homolog 3 (B7-H3), a member of the immunoglobulin superfamily, is also known CD276, which contains two Ig-like C2-type (immunoglobulin-like) domains and two Ig-like V-type (immunoglobulin-like) domains. B7-H3 may participate in the regulation of T-cell-mediated immune response. B7-H3 also plays a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. Furthermore, B7-H3 is involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. It could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Monoclonal antibody 8H9 I-124 124I-8H9; 124I-8H9-(B7-H3) Phase 2 Clinical Memorial Sloan Kettering Cancer Center Glioma Details
Anti-CD276 CAR T-cell therapy (Persongen ) Phase 1 Clinical Persongen Biotherapeutics (Suzhou) Co Ltd Stomach Neoplasms; Osteosarcoma; Neuroblastoma; Lung Neoplasms Details
CD-276-targeted Chimeric Antigen Receptor T Cell Therapy CD276 CAR-T Shenzhen University General Hospital Details
EGFR/B7H3 CAR-T EGFR/B7H3 CAR-T Second Affiliated Hospital Of Guangzhou Medical University Details
DS-5573 DS-5573; DS-5573a Daiichi Sankyo Co Ltd Details
B7-H3-targeting CAR-T cell therapy Beijing Tiantan Hospital, Capital Medical University Details
B7-H3 CAR T-cell therapy(Stanford University) B7-H3CART Phase 1 Clinical Stanford University Nervous System Diseases Details
Obrindatamab MGD-009; B7-H3 x CD3 Phase 2 Clinical Macrogenics Inc Sarcoma, Synovial; Melanoma; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Neuroblastoma; Neurofibrosarcoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Wilms Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma Details
4SCAR-276 4SCAR-276 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Solid tumours Details
SCRI-CARB7H3 SCRI-CARB7H3 Phase 1 Clinical Seattle Children'S Hospital Neuroblastoma; Neoplasms, Germ Cell and Embryonal; Melanoma; Choroid Plexus Neoplasms; Glioma; Diffuse Intrinsic Pontine Glioma; Neuroectodermal Tumors, Primitive; Sarcoma; Sarcoma, Clear Cell; Neurofibrosarcoma; Sarcoma, Ewing; Osteosarcoma; Retinoblastoma; Solid tumours; Sarcoma, Synovial; Central Nervous System Neoplasms; Wilms Tumor; Desmoplastic Small Round Cell Tumor; Rhabdoid Tumor; Carcinoma; Hepatoblastoma; Rhabdomyosarcoma; Ependymoma; Teratoma; Medulloblastoma Details
B7-H3 CAR-T cell therapy (Boyuan Runsheng Pharma) Phase 2 Clinical Boyuan Runsheng Pharma (Hangzhou) Co Ltd Solid tumours; Glioblastoma Details
Fully Human B7H3 CAR-T Cells Therapy fhB7H3.CAR-Ts Phase 2 Clinical The Affiliated Hospital Of Xuzhou Medical University Ovarian Neoplasms; Carcinoma, Hepatocellular Details
Mirzotamab clezutoclax ABBV-155 Phase 1 Clinical Abbvie Inc Solid tumours; Neoplasms Details
TAA-06 TAA06-UCAR-γδT; TAA-06 Phase 1 Clinical Persongen Biotherapeutics (Suzhou) Co Ltd Solid tumours; Neuroblastoma; Colorectal Neoplasms; Lung Neoplasms; Melanoma Details
Enoblituzumab MGA-271; TJ271 Phase 2 Clinical Macrogenics Inc Carcinoma, Transitional Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Sarcoma, Ewing; Osteosarcoma; Neuroblastoma; Urethral Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Wilms Tumor; Carcinoma, Renal Cell; Abdominal Neoplasms; Desmoplastic Small Round Cell Tumor; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma; Ovarian Neoplasms; Solid tumours Details
TAK-280 MVC-280; TAK-280 Phase 2 Clinical Maverick Therapeutics Inc Solid tumours; Neoplasms; Neoplasm Metastasis Details
BAT-8009 BAT8009; BAT-8009 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours Details
XmAb-808 XmAb808 Phase 1 Clinical Xencor Inc Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Ifinatamab deruxtecan DS-7300; DS-7300a; MABX-9001a Phase 2 Clinical Daiichi Sankyo Co Ltd Solid tumours; Small Cell Lung Carcinoma Details
Vobramitamab duocarmazine MGC-018 Phase 3 Clinical Macrogenics Inc Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Pancreatic Ductal; Melanoma Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message